Udai Banerji

Professor Udai Banerji is Deputy Head of the Drug Development Unit. He conducts Phase I trials at the Royal Marsden in his capacity as an Honorary Consultant in Medical Oncology. His interests include the discovery and applications of HSP90, PI3K, AKT, RAF and CHK1 inhibitors. He has been a principal investigator of over 25 phase I studies and has been a sub-investigator on over 100 phase I studies. In addition to Phase 1 trials, Professor Banerji’s independent laboratory interests include the use of pharmacodynamic biomarkers. He heads the Clinical PD Biomarker Group at The Institute of Cancer Research, which focuses on the quantification of biomarkers in normal tissue (platelet-rich plasma, peripheral blood mononuclear cells and hair follicles) and tumour tissue to be used as pharmacodynamic biomarkers in Phase I studies. He also runs a laboratory team (clinical pharmacology-adaptive therapy group) with interests in understanding dynamic signalling networks using cell lines and patie